ESR2 and breast cancer: Laboratory experiments, animal models, and epidemiological research have suggested anti-cancer properties of EGCG, particularly in estrogen receptor-alpha (ERα) positive breast cancer cells, where it has been shown to inhibit growth by reducing estrogen receptor-beta (ERβ) abundance and increasing p53 and p21 levels in a dose-dependent manner [5].